Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.
非糖尿病患者使用胰高血糖素樣肽-1 (GLP-1) 受體激動劑進行減重管理的療效。
Cureus 2024-08-21
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.
GLP-1 受體激動劑用於肥胖治療:作為一種有前途的方法。
Front Endocrinol (Lausanne) 2023-11-06
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
GLP-1受體激動劑在減重和安全性方面的差異:來自調節期的非隨機多中心研究。
Prim Care Diabetes 2023-08-01
Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.
GLP-1受體激動劑在達到減重和改善超重和肥胖人群心血管結果中的作用。
J Am Heart Assoc 2023-08-01
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
GLP-1激動劑在肥胖症中的新興角色:隨機對照試驗的全面回顧。
Int J Mol Sci 2023-07-18
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
GLP-1RAs(胰高血糖素樣肽-1受體激動劑)對超重或肥胖非糖尿病人群的減重效應:一項隨機對照試驗的系統性回顧與荟萃分析及試驗序列分析。
Am J Clin Nutr 2023-09-05
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
肥胖且無糖尿病個體中胰高血糖素樣肽-1受體激動劑對體重和心臟代謝參數的功效和安全性:系統性回顧和荟萃分析。
Endocr Pract 2024-02-06
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17